Join us for a virtual KOL event with Elevar Therapeutics, featuring Amit Mahipal, MBBS, MPH (University Hospitals Seidman Cancer Center, Case Western Reserve University) and Ghassan K. Abou-Alfa, MD (Memorial Sloan Kettering Cancer Center) who will discuss the current treatment landscape for patients suffering from unresectable hepatocellular carcinoma (uHCC), along with the potential for rivoceranib, a highly potent VEGFR-2 inhibitor, as a potential treatment solution for patients with uHCC.

The discussion will focus on data from the Phase 3 CARES 310 study, evaluating rivoceranib as a combination therapy versus sorafenib in the first-line setting for uHCC. Orphan drug designations for rivoceranib have been granted in uHCC (U.S.) and the FDA has proposed a May 2024 PDUFA date.

Saeho Chong, PhD, CEO of Elevar Therapeutics, will provide an overview of the company’s next steps and future directions, providing insight into the recent new drug application (NDA) acceptance by the FDA.

A live question and answer session will follow the formal presentations.